

1 April 2026

*Not for release to US wire services or distribution in the United States*

## All resolutions passed at the Extraordinary General Meeting

**Philadelphia PA and Phoenix AZ, 1 April 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), wishes to advise that all resolutions presented at the Extraordinary General Meeting of Shareholders held today were carried out by a poll and approved by shareholders. In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act, the Company advises that details of the resolutions and votes received in respect of each resolution are set out in the attached summary.

Botanix expresses its sincere appreciation to investors for their strong support of the resolutions for the capital raising, which comprises a two-tranche placement (**Placement**) that received commitments for A\$40,000,000 of new fully paid ordinary shares in Botanix (**New Shares**) and a Security Purchase Plan (**SPP**) underwritten to A\$5,000,000, with the ability to accept oversubscriptions. Details regarding eligibility to participate in the SPP are set out in the prospectus dated 11 March 2026 (**Prospectus**). Capitalised terms not otherwise defined in this announcement have the meaning given to those terms in the Prospectus. The Prospectus contains full details of the terms and conditions of the SPP (and the broader capital raising).

The Company is also offering participants in the Placement and SPP options on a 1:1 basis (**New Options**) with an exercise price of A\$0.06, expiring on 31 January 2027.

At today’s meeting, the Company obtained shareholder approval for the issue of New Securities under the SPP, New Options under the Placement and New Shares under tranche 2 of the Placement. Directors and the CEO have shown support for the capital raising by committing approximately A\$500,000 in aggregate under Tranche 2 of the Placement.

Following shareholder approval, the Company confirms that all components of the capital raising will proceed as announced on 17 February 2026. Botanix advises that eligible shareholders are still able to subscribe for the SPP, which closes at 5:00pm (AEST) on Monday 13 April 2026. A summary of the key dates for the capital raising is provided below.

Proceeds from the issue of New Shares under the Placement and SPP are intended to be used towards Active Pharmaceutical Ingredient (**API**) purchases and manufacturing components, alternate API supplier setup, advertising and marketing initiatives, operating expenses and working capital and transaction costs.

For personal use only

#### Upcoming Important Dates

Settlement of Tranche 2 of Placement	Thursday, 9 April 2026
Issue and allotment of New Shares under Tranche 2 of Placement	Friday, 10 April 2026
Closing date for SPP Offer and Placement Options Offer under Prospectus	Monday, 13 April 2026 at 5:00pm (AEST)
Settlement of SPP Offer and Placement Options Offer	Friday, 17 April 2026
Announcement of results of the SPP Offer	Friday, 17 April 2026
Issue and allotment of New Securities under the Offers	Monday, 20 April 2026

Release authorised by the Board of Directors.

#### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more please visit: <http://www.botanixpharma.com/>

#### For more information, please contact:

General enquiries  
Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

Investor enquiries  
Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

Media enquiries  
Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

#### Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra*® and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this announcement in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.

# Disclosure of Proxy Votes

## Botanix Pharmaceuticals Limited

General Meeting

Wednesday, 01 April 2026



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Approval to issue Shares and Options to Tranche 2 placees who are Unrelated Investors - This is an Interconditional Resolution	P	186,443,322	181,332,164 97.26%	1,943,509 1.04%	4,840,772	3,167,649 1.70%	292,907,571 99.34%	1,943,509 0.66%	4,840,772	Carried
2 Approval to issue Options to Tranche 1 placees - This is an Interconditional Resolution	P	187,915,334	181,338,914 96.50%	3,408,771 1.81%	3,340,239	3,167,649 1.69%	292,914,321 98.85%	3,408,771 1.15%	3,340,239	Carried
3 Approval to issue SPP Securities to Eligible Shareholders - This is an Interconditional Resolution	P	559,831,666	554,957,034 99.13%	1,706,983 0.30%	1,587,933	3,167,649 0.57%	666,613,895 99.74%	1,706,983 0.26%	1,587,933	Carried
4 Approval to issue SPP Shortfall to Sub-underwriters - This is an Interconditional Resolution	P	531,167,122	524,049,957 98.66%	3,859,516 0.73%	34,150	3,257,649 0.61%	635,796,818 99.40%	3,859,516 0.60%	34,150	Carried
5 Approval to issue Sub-underwriter Options to Sub-underwriters - This is an Interconditional Resolution	P	531,061,002	523,960,455 98.66%	3,842,898 0.72%	140,270	3,257,649 0.61%	635,707,316 99.40%	3,842,898 0.60%	140,270	Carried
6 Approval to issue Shares and Options to Mr Vince Ippolito (and/or his nominee(s))	P	540,471,347	511,538,719 94.65%	25,880,019 4.79%	20,918,252	3,052,609 0.56%	623,080,540 96.01%	25,880,019 3.99%	20,918,252	Carried
7 Approval to issue Shares and Options to Mr Danny Sharp (and/or his nominee(s))	P	550,230,533	516,213,026 93.82%	30,964,898 5.63%	11,159,066	3,052,609 0.55%	627,754,847 95.30%	30,964,898 4.70%	11,159,066	Carried
8 Approval to issue Shares and Options to Dr Stewart Washer (and/or his nominee(s))	P	542,138,551	508,154,045 93.73%	30,931,897 5.71%	19,251,048	3,052,609 0.56%	619,695,866 95.25%	30,931,897 4.75%	19,251,048	Carried



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval to issue Shares and Options to Dr Bill Bosch (and/or his nominee(s))	P	529,461,983	495,558,665 93.60%	30,850,709 5.83%	31,927,616	3,052,609 0.58%	607,100,486 95.16%	30,850,709 4.84%	31,927,616	Carried
10 Approval to issue Shares and Options to Dr Patricia Walker (and/or her nominee(s))	P	555,447,061	523,111,633 94.18%	29,282,819 5.27%	5,942,538	3,052,609 0.55%	634,653,454 95.59%	29,282,819 4.41%	5,942,538	Carried
11 Ratification of Tranche 1 Placement Shares issued under Listing Rule 7.1	P	181,326,667	164,713,525 90.84%	12,728,356 7.02%	12,060,469	3,884,786 2.14%	277,006,069 95.61%	12,728,356 4.39%	12,060,469	Carried



personal use